NASDAQ:ANGO - AngioDynamics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$20.62 +0.08 (+0.39 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$20.62
Today's Range$20.00 - $20.78
52-Week Range$14.97 - $20.78
Volume96,057 shs
Average Volume169,700 shs
Market Capitalization$755.96 million
P/E Ratio28.25
Dividend YieldN/A
Beta1.01

About AngioDynamics (NASDAQ:ANGO)

AngioDynamics logoAngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ANGO
CUSIP03475V10
Phone518-795-1400

Debt

Debt-to-Equity Ratio0.16
Current Ratio2.88
Quick Ratio1.84

Price-To-Earnings

Trailing P/E Ratio28.25
Forward P/E Ratio27.86
P/E Growth1.85

Sales & Book Value

Annual Sales$349.64 million
Price / Sales2.17
Cash Flow$1.4152 per share
Price / Cash14.57
Book Value$14.00 per share
Price / Book1.47

Profitability

EPS (Most Recent Fiscal Year)$0.73
Net Income$5 million
Net Margins0.97%
Return on Equity5.11%
Return on Assets3.81%

Miscellaneous

Employees1,250
Outstanding Shares36,810,000

AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings results on Thursday, March, 29th. The medical instruments supplier reported $0.25 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.20 by $0.05. The medical instruments supplier earned $83.85 million during the quarter, compared to the consensus estimate of $86.13 million. AngioDynamics had a net margin of 0.97% and a return on equity of 5.11%. View AngioDynamics' Earnings History.

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release their next quarterly earnings announcement on Monday, July, 16th 2018. View Earnings Estimates for AngioDynamics.

What price target have analysts set for ANGO?

7 analysts have issued 1-year price objectives for AngioDynamics' stock. Their predictions range from $16.00 to $21.00. On average, they expect AngioDynamics' share price to reach $17.5825 in the next year. View Analyst Ratings for AngioDynamics.

Who are some of AngioDynamics' key competitors?

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the folowing people:
  • Mr. James C. Clemmer, Pres, CEO & Director (Age 54)
  • Mr. Michael C. Greiner, Exec. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Stephen A. Trowbridge, Sr. VP, Gen. Counsel & Assistant Sec. (Age 44)
  • Mr. Chad T. Campbell, Sr. VP & Gen. Mang. of Global Vascular Access (Age 47)
  • Mr. Robert A. Simpson, Sr. VP Peripheral Vascular (Age 46)

Has AngioDynamics been receiving favorable news coverage?

Press coverage about ANGO stock has been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.12 on Accern's scale. They also assigned media headlines about the medical instruments supplier an impact score of 44.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.87%), Dimensional Fund Advisors LP (8.40%), Wells Fargo & Company MN (3.30%), Fort Washington Investment Advisors Inc. OH (2.79%), JPMorgan Chase & Co. (2.43%) and Segall Bryant & Hamill LLC (1.77%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, David F Burgstahler, James C Clemmer and Jan Stern Reed. View Institutional Ownership Trends for AngioDynamics.

Which major investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Systematic Financial Management LP, American Century Companies Inc., Schwab Charles Investment Management Inc., Spark Investment Management LLC, Prudential Financial Inc., California Public Employees Retirement System, Russell Investments Group Ltd. and Lapides Asset Management LLC. View Insider Buying and Selling for AngioDynamics.

Which major investors are buying AngioDynamics stock?

ANGO stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Segall Bryant & Hamill LLC, BlackRock Inc., Heartland Advisors Inc., Millennium Management LLC, Fort Washington Investment Advisors Inc. OH, Wells Fargo & Company MN and Mackay Shields LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $20.62.

How big of a company is AngioDynamics?

AngioDynamics has a market capitalization of $755.96 million and generates $349.64 million in revenue each year. The medical instruments supplier earns $5 million in net income (profit) each year or $0.73 on an earnings per share basis. AngioDynamics employs 1,250 workers across the globe.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]


MarketBeat Community Rating for AngioDynamics (ANGO)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  464
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AngioDynamics (NASDAQ:ANGO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for AngioDynamics in the last 12 months. Their average twelve-month price target is $17.5825, suggesting that the stock has a possible downside of 14.73%. The high price target for ANGO is $21.00 and the low price target for ANGO is $16.00. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.432.432.202.40
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.5825$17.5825$18.50$18.50
Price Target Upside: 14.73% downside6.97% downside17.76% upside8.63% upside

AngioDynamics (NASDAQ:ANGO) Consensus Price Target History

Price Target History for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$16.33MediumView Rating Details
4/3/2018UBSUpgradeMarket Perform ➝ OutperformMediumView Rating Details
4/2/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$16.50 ➝ $17.00LowView Rating Details
1/5/2018Craig HallumDowngradeBuy ➝ HoldHighView Rating Details
9/29/2017KeyCorpReiterated RatingHoldHighView Rating Details
7/19/2017BarclaysLower Price TargetEqual Weight$17.00 ➝ $16.00LowView Rating Details
7/4/2017Cantor FitzgeraldBoost Price TargetOverweight$20.00 ➝ $21.00LowView Rating Details
(Data available from 5/26/2016 forward)

Earnings

AngioDynamics (NASDAQ:ANGO) Earnings History and Estimates Chart

Earnings by Quarter for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO) Earnings Estimates

2018 EPS Consensus Estimate: $0.74
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.14$0.18$0.16
Q2 20182$0.15$0.16$0.16
Q3 20182$0.20$0.23$0.22
Q4 20182$0.15$0.26$0.21

AngioDynamics (NASDAQ ANGO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/16/2018$0.21N/AView Earnings Details
3/29/2018Q3 2018$0.20$0.25$86.13 million$83.85 millionViewListenView Earnings Details
1/4/2018Q2 2018$0.16$0.16$88.15 million$86.70 millionViewListenView Earnings Details
9/28/2017Q1 2018$0.16$0.12$86.12 million$85.40 millionViewN/AView Earnings Details
7/18/2017Q4 2017$0.16$0.19$90.72 million$86.90 millionViewN/AView Earnings Details
3/30/2017Q3 2017$0.15$0.19$88.29 million$85.60 millionViewN/AView Earnings Details
1/6/2017Q217$0.16$0.19$91.09 million$89.00 millionViewListenView Earnings Details
10/5/2016Q117$0.13$0.17$86.09 million$88.10 millionViewN/AView Earnings Details
7/13/2016Q416$0.16$0.19$88.64 million$93.40 millionViewListenView Earnings Details
4/7/2016Q3$0.14$0.15$85.43 million$87.40 millionViewListenView Earnings Details
1/7/2016Q216$0.14$0.14$88.67 million$89.20 millionViewN/AView Earnings Details
10/8/2015Q116$0.11$0.11$84.70 million$83.70 millionViewN/AView Earnings Details
7/16/2015Q415$0.14$0.14$91.67 million$90.90 millionViewListenView Earnings Details
4/9/2015Q315$0.15$0.12$88.69 million$86.60 millionViewN/AView Earnings Details
1/8/2015Q215$0.15$0.17$90.90 million$92.10 millionViewN/AView Earnings Details
10/9/2014Q115$0.11$0.16$85.35 million$87.30 millionViewListenView Earnings Details
7/23/2014Q414$0.12$0.18$93.65 million$94.07 millionViewListenView Earnings Details
4/9/2014Q314$0.09$0.16$86.85 million$88.20 millionViewListenView Earnings Details
1/9/2014Q2$0.07$0.14$87.54 million$88.60 millionViewListenView Earnings Details
10/10/2013Q114$0.03$0.04$82.54 million$83.60 millionViewN/AView Earnings Details
7/11/2013Q4 2013$0.06$0.07$86.43 million$90.00 millionViewN/AView Earnings Details
4/8/2013Q3 2013$0.05$0.08$81.70 million$81.60 millionViewN/AView Earnings Details
1/3/2013Q2 2013$0.09$0.10$87.40 million$87.00 millionViewN/AView Earnings Details
10/8/2012Q113$0.09$0.10$84.35 million$83.40 millionViewN/AView Earnings Details
7/12/2012$0.08$0.09ViewN/AView Earnings Details
4/4/2012$0.07$0.09ViewN/AView Earnings Details
1/5/2012$0.12$0.13ViewN/AView Earnings Details
10/6/2011$0.09$0.08ViewN/AView Earnings Details
7/14/2011$0.10$0.11ViewN/AView Earnings Details
4/5/2011$0.12$0.15ViewN/AView Earnings Details
1/4/2011$0.12$0.13ViewN/AView Earnings Details
10/7/2010Q1 2011$0.08$0.08ViewN/AView Earnings Details
7/15/2010Q4 2010$0.13$0.15ViewN/AView Earnings Details
3/31/2010Q3 2010$0.12$0.13ViewN/AView Earnings Details
1/5/2010Q2 2010$0.11$0.13ViewN/AView Earnings Details
10/6/2009Q1 2010$0.08$0.09ViewN/AView Earnings Details
7/16/2009Q4 2009$0.15$0.14ViewN/AView Earnings Details
4/2/2009Q3 2009$0.12$0.15ViewN/AView Earnings Details
1/6/2009Q2 2009$0.12$0.12ViewN/AView Earnings Details
10/2/2008Q1 2009$0.11$0.09ViewN/AView Earnings Details
7/24/2008Q4 2008$0.17$0.20ViewN/AView Earnings Details
4/2/2008Q3 2008$0.13$0.14ViewN/AView Earnings Details
1/3/2008Q2 2008$0.13$0.13ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AngioDynamics (NASDAQ:ANGO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AngioDynamics (NASDAQ ANGO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 97.62%
Insider Trading History for AngioDynamics (NASDAQ:ANGO)
Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ ANGO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/24/2017Jan Stern ReedDirectorBuy316$16.00$5,056.00316View SEC Filing  
7/21/2017James C ClemmerCEOBuy5,000$15.79$78,950.0086,683View SEC Filing  
7/20/2017James C ClemmerCEOBuy20,000$15.64$312,800.0086,683View SEC Filing  
4/12/2017Avista Capital Partners Gp, LlMajor ShareholderSell2,350,000$16.00$37,600,000.00View SEC Filing  
8/5/2016Avista Capital Partners Gp, LlMajor ShareholderSell2,241,000$14.62$32,763,420.00View SEC Filing  
8/5/2016David F BurgstahlerDirectorSell2,250,000$14.62$32,895,000.0023,988View SEC Filing  
5/6/2016Charles R GreinerVPSell3,508$12.31$43,183.4820,910View SEC Filing  
4/25/2016Stephen A TrowbridgeSVPSell12,940$12.30$159,162.0032,469View SEC Filing  
4/14/2014Matthew KapustaSVPBuy1,000$13.90$13,900.0027,005View SEC Filing  
10/18/2013Vincent BucciDirectorBuy5,000$15.20$76,000.00View SEC Filing  
10/17/2013Howard W DonnellyDirectorSell20,000$15.06$301,200.00View SEC Filing  
7/22/2013Kevin J GouldDirectorBuy2,700$12.00$32,400.00View SEC Filing  
5/9/2013Charles R GreinerVPSell1,495$10.38$15,518.10View SEC Filing  
3/12/2013Vincent BucciDirectorBuy85,000$10.77$915,450.00View SEC Filing  
2/14/2013Vincent BucciDirectorBuy2,000$12.17$24,340.00View SEC Filing  
1/11/2013Kevin J GouldDirectorBuy2,700$11.58$31,266.00View SEC Filing  
11/5/2012Jeffrey GoldDirectorBuy1,000$10.56$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AngioDynamics (NASDAQ ANGO) News Headlines

Source:
DateHeadline
Global Vascular Access Devices Market Growth Opportunities: Edwards Lifesciences Corporation, AngioDynamics, BectonGlobal Vascular Access Devices Market Growth Opportunities: Edwards Lifesciences Corporation, AngioDynamics, Becton
www.marketwatch.com - May 22 at 9:10 AM
AngioDynamics, Inc. (ANGO) Expected to Announce Quarterly Sales of $88.99 MillionAngioDynamics, Inc. (ANGO) Expected to Announce Quarterly Sales of $88.99 Million
www.americanbankingnews.com - May 16 at 5:01 AM
AngioDynamics (ANGO) vs. Obalon Therapeutics (OBLN) Financial ReviewAngioDynamics (ANGO) vs. Obalon Therapeutics (OBLN) Financial Review
www.americanbankingnews.com - May 15 at 12:29 PM
AngioDynamics, Inc. (ANGO) Given Average Rating of "Buy" by BrokeragesAngioDynamics, Inc. (ANGO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 14 at 5:16 PM
 Brokerages Anticipate AngioDynamics, Inc. (ANGO) to Post $0.21 EPS Brokerages Anticipate AngioDynamics, Inc. (ANGO) to Post $0.21 EPS
www.americanbankingnews.com - May 14 at 1:17 AM
Why Is AngioDynamics (ANGO) Up 13.9% Since Its Last Earnings Report?Why Is AngioDynamics (ANGO) Up 13.9% Since Its Last Earnings Report?
finance.yahoo.com - April 30 at 9:28 AM
$88.99 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter$88.99 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - April 28 at 3:04 AM
Global Tumor Ablation Market Competitive landscape: LLC., Boston Scientific Corporation, AngioDynamicsGlobal Tumor Ablation Market Competitive landscape: LLC., Boston Scientific Corporation, AngioDynamics
www.marketwatch.com - April 27 at 9:48 AM
 Brokerages Expect AngioDynamics, Inc. (ANGO) Will Announce Earnings of $0.21 Per Share Brokerages Expect AngioDynamics, Inc. (ANGO) Will Announce Earnings of $0.21 Per Share
www.americanbankingnews.com - April 26 at 1:26 PM
AngioDynamics (ANGO) & Its Peers Head to Head ComparisonAngioDynamics (ANGO) & Its Peers Head to Head Comparison
www.americanbankingnews.com - April 24 at 11:02 PM
Global Varicose Vein Treatment Market Overview 2017-2026: Sciton Inc, Energist Ltd, AngioDynamics IncGlobal Varicose Vein Treatment Market Overview 2017-2026: Sciton Inc, Energist Ltd, AngioDynamics Inc
www.marketwatch.com - April 24 at 9:16 AM
AngioDynamics (ANGO) Price Target Increased to $21.00 by Analysts at Cantor FitzgeraldAngioDynamics (ANGO) Price Target Increased to $21.00 by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - April 19 at 11:52 PM
AngioDynamics, Inc. (ANGO) Given Average Recommendation of "Buy" by AnalystsAngioDynamics, Inc. (ANGO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 19 at 5:40 PM
AngioDynamics (ANGO) Upgraded to B- by TheStreetAngioDynamics (ANGO) Upgraded to B- by TheStreet
www.americanbankingnews.com - April 18 at 10:41 AM
AngioDynamics (ANGO) Downgraded by BidaskClubAngioDynamics (ANGO) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 6:23 PM
AngioDynamics to Present at Two Investor Conferences in MayAngioDynamics to Present at Two Investor Conferences in May
finance.yahoo.com - April 10 at 4:36 PM
AngioDynamics (ANGO) Raised to Strong-Buy at BidaskClubAngioDynamics (ANGO) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - April 10 at 11:28 AM
Zacks: Brokerages Expect AngioDynamics, Inc. (ANGO) to Announce $0.21 EPSZacks: Brokerages Expect AngioDynamics, Inc. (ANGO) to Announce $0.21 EPS
www.americanbankingnews.com - April 9 at 3:21 PM
AngioDynamics (ANGO) Upgraded to "Buy" by Zacks Investment ResearchAngioDynamics (ANGO) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 8 at 10:49 AM
AngioDynamics (ANGO) Stock Rating Upgraded by ValuEngineAngioDynamics (ANGO) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 6 at 11:38 AM
Blog Exposure - Waters Corp. to Significantly Expand its Precision Chemistry Facility in MassachusettsBlog Exposure - Waters Corp. to Significantly Expand its Precision Chemistry Facility in Massachusetts
finance.yahoo.com - April 5 at 4:33 PM
AngioDynamics (ANGO) Product Line Strong, Debt Level HighAngioDynamics (ANGO) Product Line Strong, Debt Level High
finance.yahoo.com - April 3 at 4:37 PM
Raymond James Financial Upgrades AngioDynamics (ANGO) to OutperformRaymond James Financial Upgrades AngioDynamics (ANGO) to Outperform
www.americanbankingnews.com - April 3 at 10:43 AM
AngioDynamics (ANGO) Upgraded at UBSAngioDynamics (ANGO) Upgraded at UBS
www.americanbankingnews.com - April 3 at 7:48 AM
AngioDynamics (ANGO) PT Raised to $17.00 at Canaccord GenuityAngioDynamics (ANGO) PT Raised to $17.00 at Canaccord Genuity
www.americanbankingnews.com - April 2 at 2:38 PM
AngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates ViewAngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates View
www.zacks.com - April 2 at 9:47 AM
AngioDynamics (ANGO) Q3 2018 Earnings Conference Call TranscriptAngioDynamics (ANGO) Q3 2018 Earnings Conference Call Transcript
finance.yahoo.com - April 1 at 4:59 PM
AngioDynamics (ANGO) Downgraded by TheStreet to CAngioDynamics (ANGO) Downgraded by TheStreet to C
www.americanbankingnews.com - March 30 at 5:08 PM
AngioDynamics (ANGO) Raised to Buy at BidaskClubAngioDynamics (ANGO) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 30 at 1:06 PM
Edited Transcript of ANGO earnings conference call or presentation 29-Mar-18 12:00pm GMTEdited Transcript of ANGO earnings conference call or presentation 29-Mar-18 12:00pm GMT
finance.yahoo.com - March 30 at 9:24 AM
AngioDynamics (ANGO) Posts  Earnings Results, Beats Expectations By $0.06 EPSAngioDynamics (ANGO) Posts Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - March 30 at 7:52 AM
Head to Head Survey: AngioDynamics (ANGO) vs. Its PeersHead to Head Survey: AngioDynamics (ANGO) vs. Its Peers
www.americanbankingnews.com - March 30 at 3:06 AM
AngioDynamics beats by $0.06, misses on revenueAngioDynamics beats by $0.06, misses on revenue
seekingalpha.com - March 29 at 4:35 PM
AngioDynamics Q3 revenues down 2%; non-GAAP EPS up 32%AngioDynamics Q3 revenues down 2%; non-GAAP EPS up 32%
seekingalpha.com - March 29 at 9:41 AM
AngioDynamics misses 3Q revenue forecastsAngioDynamics misses 3Q revenue forecasts
finance.yahoo.com - March 29 at 9:41 AM
Where AngioDynamics Inc (NASDAQ:ANGO) Stands In Earnings Growth Against Its IndustryWhere AngioDynamics Inc (NASDAQ:ANGO) Stands In Earnings Growth Against Its Industry
finance.yahoo.com - March 29 at 9:41 AM
AngioDynamics (ANGO) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowAngioDynamics (ANGO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 28 at 4:33 PM
AngioDynamics, Inc. (ANGO) Receives Average Recommendation of "Hold" from BrokeragesAngioDynamics, Inc. (ANGO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 25 at 5:18 PM
AngioDynamics (ANGO) Lifted to "Hold" at BidaskClubAngioDynamics (ANGO) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - March 25 at 3:47 PM
AngioDynamics, Inc. (ANGO) Expected to Announce Earnings of $0.20 Per ShareAngioDynamics, Inc. (ANGO) Expected to Announce Earnings of $0.20 Per Share
www.americanbankingnews.com - March 23 at 3:17 PM
Global Vascular Access Devices Market Opportunities 2018: R. Bard, Braun Melsungen AG, Dickinson and Company, AngioDynamicsGlobal Vascular Access Devices Market Opportunities 2018: R. Bard, Braun Melsungen AG, Dickinson and Company, AngioDynamics
www.marketwatch.com - March 21 at 10:26 AM
AngioDynamics (ANGO) Set to Announce Earnings on WednesdayAngioDynamics (ANGO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 21 at 1:36 AM
AngioDynamics to Present at the Needham 17th Annual Healthcare ConferenceAngioDynamics to Present at the Needham 17th Annual Healthcare Conference
finance.yahoo.com - March 15 at 5:04 PM
AngioDynamics, Inc. (ANGO) Expected to Announce Quarterly Sales of $86.13 MillionAngioDynamics, Inc. (ANGO) Expected to Announce Quarterly Sales of $86.13 Million
www.americanbankingnews.com - March 8 at 7:54 AM
$0.20 Earnings Per Share Expected for AngioDynamics, Inc. (ANGO) This Quarter$0.20 Earnings Per Share Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - March 6 at 9:42 AM
Arrowstreet Capital Limited Partnership Purchases 29,400 Shares of AngioDynamics, Inc. (ANGO)Arrowstreet Capital Limited Partnership Purchases 29,400 Shares of AngioDynamics, Inc. (ANGO)
www.americanbankingnews.com - March 6 at 4:35 AM
Broadfin Capital LLC Has $28.81 Million Position in AngioDynamics, Inc. (ANGO)Broadfin Capital LLC Has $28.81 Million Position in AngioDynamics, Inc. (ANGO)
www.americanbankingnews.com - March 2 at 5:08 AM
Spark Investment Management LLC Raises Stake in AngioDynamics, Inc. (ANGO)Spark Investment Management LLC Raises Stake in AngioDynamics, Inc. (ANGO)
www.americanbankingnews.com - March 1 at 6:58 PM
AngioDynamics, Inc. (ANGO) Shares Sold by Martingale Asset Management L PAngioDynamics, Inc. (ANGO) Shares Sold by Martingale Asset Management L P
www.americanbankingnews.com - March 1 at 9:34 AM
A Look at the Performances of Abaxis’s Product CategoriesA Look at the Performances of Abaxis’s Product Categories
finance.yahoo.com - March 1 at 9:04 AM

SEC Filings

AngioDynamics (NASDAQ:ANGO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AngioDynamics (NASDAQ:ANGO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AngioDynamics (NASDAQ ANGO) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.